Third Point Sets Sights On Nabi, Again

Nov 2 2006 | 11:54am ET

If there’s one thing we’ve learned about Daniel Loeb of Third Point, it’s that he makes good on his threats.

The activist hedge fund manager has filed a proxy statement seeking to boot five members–a majority–of the board of Nabi Biopharmaceuticals, including its CEO, Thomas McLain. Third Point owns 8.4% of the Boca Raton, Fla.-based company.
 
Last month, Nabi rejected Third Point’s demand to open its books to the New York-based hedge fund; the company said its management allowed inspection of only a “limited subset” of its documents. At the time, Third Point said it would proceed with a consent solicitation.

Nabi has responded to Third Point's most recent move by releasing a statement saying that it would review Third Point’s filing and “will communicate with stockholders in due course.”

This is not the first time that Loeb and McLain have butted heads, and if history is any indication, McLain should freshen up his résumé. In April, Loeb alleged that “the longstanding relationship between Mr. McLain and the Lehman [Brothers] investment bankers will prevent the company from receiving objective advice that will lead to the creation of maximum shareholder value.” Nabi responded by hiring Bank of America, a move praised by Loeb.


In Depth

Debunking Conventional Investment Wisdom

Feb 8 2017 | 3:22pm ET

Due diligence in the hedge fund world has long involved some combination of the...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

iCapital Network: The Trump Effect On Direct Lending

Feb 23 2017 | 4:21pm ET

The arrival of the Trump Administration has raised questions among private debt...

 

From the current issue of